Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Removing barriers to address sex differences in anticancer drug toxicity

Nature Reviews Cancer volume 24, pages 161–162 (2024)Cite this article

Subjects

Despite the compelling evidence for greater toxicity in female patients, sex-specific anticancer treatment strategies are missing. Increased awareness of sex differences at all stages of drug development by researchers, the pharmaceutical industry, funding institutions and regulatory agencies is needed to accurately implement precision oncology.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Barriers and solutions for sex-specific anticancer drug dosing.

References

  1. Unger, J. M. et al. Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials. J. Clin. Oncol. 40, 1474–1486 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Zucker, I. & Prendergast, B. J. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol. Sex Differ. 11, 32 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Wagner, A. D. et al. Gender medicine and oncology: report and consensus of an ESMO Workshop. Ann. Oncol. 30, 1914–1928 (2019).

    Article  CAS  PubMed  Google Scholar 

  4. Hopkins, J. J. & Sawyer, M. B. Interactions of lean soft-tissue and chemotherapy toxicities in patients receiving anti-cancer treatments. Cancer Chemother. Pharmacol. 82, 1–29 (2018).

    Article  CAS  PubMed  Google Scholar 

  5. Trinkner, P. et al. Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy – A systematic review and meta-analysis. Eur. J. Cancer 184, 151–171 (2023).

    Article  CAS  PubMed  Google Scholar 

  6. Wagner, A. D. et al. Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database. J. Clin. Oncol. 38, 4029–4029 (2020).

    Article  Google Scholar 

  7. Ye, Y. et al. Sex-associated molecular differences for cancer immunotherapy. Nat. Commun. 11, 1779 (2020).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  8. Shah, M., Rahman, A., Theoret, M. R. & Pazdur, R. The drug-dosing conundrum in oncology — when less is more. N. Eng. J. Med. 385, 1445–1447 (2021).

    Article  Google Scholar 

  9. Jenei, K., Meyers, D. E. & Prasad, V. The inclusion of women in global oncology drug trials over the past 20 years. JAMA Oncol. 7, 1569–1570 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Jenei, K., Raymakers, A., Meyers, D. E. & Prasad, V. Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015–2020. J. Cancer Policy 30, 100311 (2021).

    Article  PubMed  Google Scholar 

  11. Özdemir, B. C., Richters, A., Espinosa da Silva, C. & Berner, A. M. Cancer researchers’ perceptions of the importance of the sex of cell lines, animals, and human samples for cancer biology research. iScience 26, 106212 (2023).

    Article  ADS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

    Berna C. Özdemir

Authors
  1. Berna C. Özdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Berna C. Özdemir.

Ethics declarations

Competing interests

The author declares receiving honoraria paid to her institution for lectures and advisory boards from BMS, MSD, Merck, Ipsen, Roche, Pfizer, Novartis, Janssen and Sanofi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Özdemir, B.C. Removing barriers to address sex differences in anticancer drug toxicity. Nat Rev Cancer 24, 161–162 (2024). https://doi.org/10.1038/s41568-023-00651-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41568-023-00651-w

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer